| Literature DB >> 29701725 |
Ana Sanchez1, Maria Blanco2, Begoña Correa3, Ricardo I Perez-Martin4, Carmen G Sotelo5.
Abstract
Fish discards and subproducts may represent an important source of raw material, not only for the food industry, but for other different kind of industries, such as the nutraceutical and cosmetic industries. Collagen, which is mainly obtained from animal skins, is an important structural protein in the animal kingdom having many different applications. It is well known that fish skins constitute a significant subproduct in the fishery industry, especially in the case of some species, where fish skins may represent up to 20% of the total body weight of fish. Peptides from collagen hydrolysates have been described to be useful for preventing skin aging and osteoarthritis, however, the mechanism for these biological activities is not well known. Fibroblasts are the main cell types involved in the collagen synthesis, and in the present work, human dermal fibroblasts have been exposed to the treatment of collagen peptides of two different molecular weight ranges. Results show that higher molecular weight collagen peptides produce higher synthesis of collagen type I mRNA and, therefore, it may suggest that prior molecular weight selection may be an important step to maximize the effect of collagen hydrolysates on collagen type I synthesis by dermal fibroblasts.Entities:
Keywords: collagen hydrolysates; commercial collagen hydrolysates; fibroblast; fish collagen; type I collagen mRNA
Mesh:
Substances:
Year: 2018 PMID: 29701725 PMCID: PMC5983275 DOI: 10.3390/md16050144
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1(A) Size exclusion chromatography profile of the alcalase hydrolyzed Blue shark (Prionace glauca) skin collagen hydrolysate (PGLA-CH) retained fraction (RF). (B) Size exclusion chromatography profile of the alcalase hydrolyzed PGLA-CH permeate fraction (PF).
Figure 2(A) Size exclusion chromatography profile of the commercial collagen hydrolysate (C-CH) RF; (B) Size exclusion chromatography profile of the C-CH PF.
Amino acid composition of PGLA-CH RF, PGLA-CH PF, C-CH RF, and C-CH PF (residues/100 residues). Values are means of three determinations ± standard deviation.
| Amino Acid | PGLA-CH RF | PGLA-CH PF | C-CH RF | C-CH PF |
|---|---|---|---|---|
| Aspartic acid | 4.39 ± 0.02 | 3.43 ± 0.03 | 4.98 ± 0.01 | 3.37 ± 0.05 |
| Threonine | 2.19 ± 0.02 | 2.31 ± 0.02 | 2.18 ± 0.01 | 2.44 ± 0.03 |
| Serine | 4.09 ± 0.15 | 4.35 ± 0.13 | 3.57 ± 0.10 | 3.71 ± 0.01 |
| Glutamic acid | 7.18 ± 0.02 | 6.92 ± 0.04 | 7.61 ± 0.05 | 5.99 ± 0.19 |
| Glycine | 33.97 ± 0.06 | 34.20 ± 0.16 | 32.56 ± 0.02 | 38.90 ± 0.21 |
| Alanine | 11.40 ± 0.10 | 13.55 ± 0.10 | 11.57 ± 0.01 | 11.46 ± 0.01 |
| Cysteine | 0.20 ± 0.03 | 0.29 ± 0.04 | 0.23 ± 0.07 | 0.28 ± 0.01 |
| Valine | 1.81 ± 0.05 | 2.48 ± 0.05 | 2.53 ± 0.03 | 3.15 ± 0.02 |
| Methionine | 1.38 ± 0.01 | 1.87 ± 0.11 | 0.86 ± 0.00 | 1.13 ± 0.03 |
| Isoleucine | 1.92 ± 0.02 | 1.49 ± 0.03 | 1.11 ± 0.01 | 1.58 ± 0.02 |
| Leucine | 2.07 ± 0.04 | 2.63 ± 0.01 | 3.21 ± 0.01 | 4.44 ± 0.01 |
| Tyrosine | 0.00 ± 0.00 | 0.09 ± 0.12 | 0.65 ± 0.01 | 1.22 ± 0.13 |
| Phenylalanine | 1.50 ± 0.01 | 1.49 ± 0.03 | 1.73 ± 0.02 | 2.79 ± 0.07 |
| Histidine | 0.49 ± 0.00 | 0.57 ± 0.01 | 0.42 ± 0.01 | 0.53 ± 0.02 |
| Lysine | 2.61 ± 0.02 | 2.50 ± 0.06 | 3.05 ± 0.01 | 2.76 ± 0.04 |
| Arginine | 4.95± 0.01 | 5.31± 0.01 | 4.65 ± 0.04 | 4.73 ± 0.22 |
| Hydroxyproline | 8.29 ± 0.04 | 6.07 ± 0.11 | 8.62 ± 0.07 | 5.07 ± 0.40 |
| Proline | 11.56 ± 0.02 | 10.46 ± 0.02 | 10.49 ± 0.06 | 6.45 ± 0.09 |
Figure 3Relative quantification (RQ) values for collagen type I mRNA with increasing amounts of PGLA-CH (μg/mL) added to fibroblasts. RQ values are the means of five determinations and error bars are standard deviations. Blue bars: 50 μg/mL CH, Pink bars: 100 μg/mL CH, Yellow bars: 500 μg/mL. (A) RQ values obtained after 24 h treatment with PGLA-CH RF. (B) RQ values obtained after 24 h treatment with PGLA-CH PF. (C) RQ values obtained after 48 h treatment with PGLA-CH RF. (D) RQ values obtained after 48 h treatment with PGLA-CH PF.
Figure 4RQ values for collagen type I mRNA with increasing amounts of C-CH (μg/mL) added to fibroblasts. RQ values are the means of five determinations and error bars are standard deviations. Blue bars: 50 μg/mL CH, Pink bars: 100 μg/mL CH, Yellow bars: 500 μg/mL. (A) RQ values obtained after 24 h treatment with C-CH RF. (B) RQ values obtained after 24 h treatment with C-CH PF.
Concentration of CH PF and CH RF prepared with fibroblast medium (FM) and used to treat fibroblast cells.
| Concentration | ||||
|---|---|---|---|---|
| Treatment Components | 500 µg/mL | 100 µg/mL | 50 µg/mL | Control |
| CH PF and RF | 250 µL | 50 µL | 25 µL | - |
| FM | 250 µL | 450 µL | 475 µL | 500 µL |
Sequence of primers and probes used for RQ of collagen type I.
| Primer/Probe | Sequence 5′→3′ |
|---|---|
| GAPDH-Forward | GGAAGCTCACTGGCATGGC |
| GAPDH-Reverse | TAGACGGCAGGTCAGGTCCA |
| GAPDH-Probe | VIC-CCCCACTGCCAACGTGTCAGTG-MGB |
| COL_I-Forward | ATGCCTGGTGAACGTGGT |
| COL_I-Reverse | AGGAGAGCCATCAGCACCT |
| COL_I-Probe | 6-FAM-ACCAGCATCACCTCTGTC-MGB |